EU Commission Issues Standard Marketing Authorisation for COVID-19 Vaccine Nuvaxovid

On 25 May 2022, the Committee for Human Medicinal Products (CHMP) at the European Medicines Agency recommended that the conditional marketing authorisation for the protein-based COVID-19 vaccine Nuvaxovid be converted into a standard marketing authorisation. The European Commission followed the CHMP's recommendation on 4 July 2023. A standard marketing authorisation means that the application does not need to be renewed annually. All other obligations for the pharmaceutical company remain in place.